{"component": "definition", "props": {"groups": [{"samples": [{"hash": "dJZy884wlou", "uri": "/contracts/dJZy884wlou#commercial-launch", "label": "Evg License Agreement (Gilead Sciences Inc)", "score": 30.2922649384, "published": true}, {"hash": "lXQIn8Pzk6k", "uri": "/contracts/lXQIn8Pzk6k#commercial-launch", "label": "Evg License Agreement (Gilead Sciences Inc)", "score": 30.1526355743, "published": true}, {"hash": "8xResungD9j", "uri": "https://d18rn0p25nwr6d.cloudfront.net/CIK-0000882095/95a031d0-b033-4722-a1b3-a19257b972cf.pdf", "label": "Amendment", "score": 23.9666919708, "published": false}], "snippet": "means, with respect to a Product, the first commercial sale of such Product to a Third Party occurring after Regulatory Approval for such Product.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "sale-of", "type": "clause", "offset": [55, 62]}, {"key": "a-third-party", "type": "clause", "offset": [79, 92]}, {"key": "after-regulatory-approval", "type": "clause", "offset": [103, 128]}], "size": 14, "hash": "08d5907ddf657dc1a94fb39e359a55d7", "id": 1}, {"samples": [{"hash": "bKomSlgnaHv", "uri": "/contracts/bKomSlgnaHv#commercial-launch", "label": "Exclusive License and Supply Agreement", "score": 31.3408622742, "published": true}, {"hash": "4Kk5GSQUoVE", "uri": "/contracts/4Kk5GSQUoVE#commercial-launch", "label": "Exclusive License and Supply Agreement (Eton Pharmaceuticals, Inc.)", "score": 30.3442840576, "published": true}, {"hash": "7vVCIMtxzjo", "uri": "/contracts/7vVCIMtxzjo#commercial-launch", "label": "Exclusive License and Supply Agreement (Eton Pharmaceuticals, Inc.)", "score": 29.7310066223, "published": true}], "snippet": "means the first shipment of the Product in commercial quantities for commercial sale to a third party in the Territory after receipt of all applicable regulatory approvals therefor.", "snippet_links": [{"key": "first-shipment", "type": "definition", "offset": [10, 24]}, {"key": "the-product", "type": "definition", "offset": [28, 39]}, {"key": "commercial-quantities", "type": "definition", "offset": [43, 64]}, {"key": "sale-to-a-third-party", "type": "clause", "offset": [80, 101]}, {"key": "in-the-territory", "type": "clause", "offset": [102, 118]}, {"key": "after-receipt-of", "type": "clause", "offset": [119, 135]}, {"key": "applicable-regulatory-approvals", "type": "definition", "offset": [140, 171]}], "size": 10, "hash": "7a90b06e40d6a02b869351db6298acfb", "id": 2}, {"samples": [{"hash": "l9B8qjzgPQY", "uri": "/contracts/l9B8qjzgPQY#commercial-launch", "label": "Asset Transfer and License Agreement", "score": 31.3408622742, "published": true}, {"hash": "cyuAVn9gxF0", "uri": "/contracts/cyuAVn9gxF0#commercial-launch", "label": "Asset Transfer and License Agreement (Avenue Therapeutics, Inc.)", "score": 28.1950721741, "published": true}, {"hash": "k4BTtUsRir7", "uri": "/contracts/k4BTtUsRir7#commercial-launch", "label": "Asset Transfer and License Agreement (Avenue Therapeutics, Inc.)", "score": 28.0308017731, "published": true}], "snippet": "means the first commercial sale of a Product by or on behalf of Coronado or its Affiliates or a licensee to an independent third party for human therapeutic or prophylactic use after receipt of Regulatory Approval for such Product. A sale for clinical trial, research, development, test marketing, sampling, promotional, compassionate use, or resale purposes will not be considered a first commercial sale.", "snippet_links": [{"key": "sale-of", "type": "clause", "offset": [27, 34]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [45, 63]}, {"key": "independent-third-party", "type": "definition", "offset": [111, 134]}, {"key": "receipt-of-regulatory-approval", "type": "clause", "offset": [183, 213]}, {"key": "clinical-trial", "type": "definition", "offset": [243, 257]}, {"key": "test-marketing", "type": "clause", "offset": [282, 296]}, {"key": "compassionate-use", "type": "clause", "offset": [321, 338]}], "size": 7, "hash": "8c922d94503d978bc52a7ec0d96515db", "id": 3}, {"samples": [{"hash": "hpu9ye5ee5w", "uri": "/contracts/hpu9ye5ee5w#commercial-launch", "label": "License Agreement (Ironwood Pharmaceuticals Inc)", "score": 30.5797405243, "published": true}, {"hash": "4F45aJSmFzJ", "uri": "/contracts/4F45aJSmFzJ#commercial-launch", "label": "License Agreement", "score": 23.9322376251, "published": true}, {"hash": "8xbAbzIZG8l", "uri": "/contracts/8xbAbzIZG8l#commercial-launch", "label": "License Agreement (Ironwood Pharmaceuticals Inc)", "score": 21.0876121521, "published": true}], "snippet": "means the initial First Commercial Sale of a Product in the Territory.", "snippet_links": [{"key": "sale-of", "type": "clause", "offset": [35, 42]}, {"key": "in-the-territory", "type": "clause", "offset": [53, 69]}], "size": 7, "hash": "48d7ec75cee15183a72e10d98f9ed595", "id": 4}, {"samples": [{"hash": "6lsq1xPYQ9m", "uri": "/contracts/6lsq1xPYQ9m#commercial-launch", "label": "Collaboration and License Agreement", "score": 31.3408622742, "published": true}, {"hash": "3eTykk37SRc", "uri": "/contracts/3eTykk37SRc#commercial-launch", "label": "Collaboration and License Agreement (Pozen Inc /Nc)", "score": 25.7227916718, "published": true}, {"hash": "ije5mCCq5Ha", "uri": "/contracts/ije5mCCq5Ha#commercial-launch", "label": "Collaboration and License Agreement (Horizon Pharma, Inc.)", "score": 25.3887748718, "published": true}], "snippet": "means the nationwide commercial sale, promotion and distribution of POZEN Product in the Territory following receipt of Marketing Approval in the Territory.", "snippet_links": [{"key": "commercial-sale", "type": "clause", "offset": [21, 36]}, {"key": "distribution-of", "type": "clause", "offset": [52, 67]}, {"key": "pozen-product", "type": "definition", "offset": [68, 81]}, {"key": "in-the-territory", "type": "clause", "offset": [82, 98]}, {"key": "receipt-of", "type": "clause", "offset": [109, 119]}, {"key": "marketing-approval", "type": "clause", "offset": [120, 138]}], "size": 7, "hash": "8e7536603174771f90b1cd572663b5eb", "id": 5}, {"samples": [{"hash": "hlxamEzljTf", "uri": "/contracts/hlxamEzljTf#commercial-launch", "label": "Collaboration and License Agreement (Xcel Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "cllYrBSmCCP", "uri": "/contracts/cllYrBSmCCP#commercial-launch", "label": "Collaboration and License Agreement (Pozen Inc /Nc)", "score": 21.0, "published": true}, {"hash": "4J3HFfwK0XA", "uri": "/contracts/4J3HFfwK0XA#commercial-launch", "label": "Collaboration and License Agreement (Pozen Inc /Nc)", "score": 21.0, "published": true}], "snippet": "means nationwide launch of commercial sale, promotion and distribution of a Licensed Product in the Territory following Marketing Approval for such Licensed Product.", "snippet_links": [{"key": "commercial-sale", "type": "clause", "offset": [27, 42]}, {"key": "distribution-of", "type": "clause", "offset": [58, 73]}, {"key": "licensed-product", "type": "clause", "offset": [76, 92]}, {"key": "in-the-territory", "type": "clause", "offset": [93, 109]}, {"key": "marketing-approval", "type": "clause", "offset": [120, 138]}], "size": 7, "hash": "63dd79d3182e7e7c2b5e0e5b114bf750", "id": 6}, {"samples": [{"hash": "p5IJj6Q3DQ", "uri": "/contracts/p5IJj6Q3DQ#commercial-launch", "label": "License, Development and Distribution Agreement (Natera, Inc.)", "score": 30.0978775024, "published": true}, {"hash": "gleEWGGCuri", "uri": "/contracts/gleEWGGCuri#commercial-launch", "label": "License, Development and Distribution Agreement (Natera, Inc.)", "score": 29.353181839, "published": true}, {"hash": "9tOzM94FEAy", "uri": "https://investor.natera.com/static-files/c4d97458-8f99-4379-b501-67ea0e600af6", "label": "investor.natera.com", "score": 9.9952087402, "published": false}], "snippet": "means the first sale of the Product by QIAGEN or its Affiliate for a commercial purpose (i.e., revenue) to a third party in the Territory. For the sake of clarity, Commercial Launch excludes prototype purchases, customer evaluations prior to launch, and units distributed for use in clinical trials and includes a sale of an [*] to a Laboratory Licensee as permitted under Section 6.11.", "snippet_links": [{"key": "sale-of-the-product", "type": "clause", "offset": [16, 35]}, {"key": "commercial-purpose", "type": "definition", "offset": [69, 87]}, {"key": "a-third-party", "type": "clause", "offset": [107, 120]}, {"key": "in-the-territory", "type": "clause", "offset": [121, 137]}, {"key": "customer-evaluations", "type": "clause", "offset": [212, 232]}, {"key": "prior-to-launch", "type": "clause", "offset": [233, 248]}, {"key": "in-clinical-trials", "type": "clause", "offset": [280, 298]}, {"key": "laboratory-licensee", "type": "definition", "offset": [334, 353]}], "size": 6, "hash": "f60f7a813cf8778b6e29d709c0a31fc6", "id": 7}, {"samples": [{"hash": "6gEDYiErX9F", "uri": "/contracts/6gEDYiErX9F#commercial-launch", "label": "Development Funding Agreement (Apellis Pharmaceuticals, Inc.)", "score": 30.3442840576, "published": true}, {"hash": "54cYGSdyNRY", "uri": "https://investors.apellis.com/static-files/3e75570f-33e0-4dc2-8157-c9bb84b1fb48", "label": "investors.apellis.com", "score": 9.9979467392, "published": false}], "snippet": "means, with respect to the Product and a country in the Territory, the first sale to a Third Party of such Product in such country after Regulatory Approval in such country.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "the-product", "type": "definition", "offset": [23, 34]}, {"key": "in-the-territory", "type": "clause", "offset": [49, 65]}, {"key": "sale-to-a-third-party", "type": "clause", "offset": [77, 98]}, {"key": "after-regulatory-approval", "type": "clause", "offset": [131, 156]}], "size": 6, "hash": "a8b21c76065fb763ed30b19647a45e8e", "id": 8}, {"samples": [{"hash": "1t7g0pSwVnD", "uri": "/contracts/1t7g0pSwVnD#commercial-launch", "label": "License & Supply Agreement (Priveterra Acquisition Corp.)", "score": 33.9856262207, "published": true}, {"hash": "eqsLwYws6hd", "uri": "/contracts/eqsLwYws6hd#commercial-launch", "label": "License & Supply Agreement (AEON Biopharma, Inc.)", "score": 32.7563323975, "published": true}, {"hash": "4FLZQtgeElT", "uri": "/contracts/4FLZQtgeElT#commercial-launch", "label": "License & Supply Agreement (AEON Biopharma, Inc.)", "score": 32.7097892761, "published": true}], "snippet": "means the first commercial sale by AEON or its Affiliates of Product in the Field to a distributor, wholesaler or other person engaged in the commercial business similar thereto for distribution, or to an end user or a consumer in the Territory.", "snippet_links": [{"key": "first-commercial-sale", "type": "definition", "offset": [10, 31]}, {"key": "in-the-field", "type": "clause", "offset": [69, 81]}, {"key": "other-person", "type": "definition", "offset": [114, 126]}, {"key": "engaged-in", "type": "definition", "offset": [127, 137]}, {"key": "commercial-business", "type": "definition", "offset": [142, 161]}, {"key": "for-distribution", "type": "clause", "offset": [178, 194]}, {"key": "end-user", "type": "definition", "offset": [205, 213]}, {"key": "in-the-territory", "type": "clause", "offset": [228, 244]}], "size": 5, "hash": "40181d0a25c3b6e93573e533c398693b", "id": 9}, {"samples": [{"hash": "7k8DSHBRN2O", "uri": "/contracts/7k8DSHBRN2O#commercial-launch", "label": "License and Services Agreement (Arbutus Biopharma Corp)", "score": 27.1848049164, "published": true}, {"hash": "4Hlkm74Tj9y", "uri": "/contracts/4Hlkm74Tj9y#commercial-launch", "label": "Option Agreement (Arbutus Biopharma Corp)", "score": 27.1848049164, "published": true}, {"hash": "gw7i4HxNZAQ", "uri": "/contracts/gw7i4HxNZAQ#commercial-launch", "label": "License and Services Agreement (TEKMIRA PHARMACEUTICALS Corp)", "score": 25.2354545593, "published": true}], "snippet": "means the first bona fide commercial sale of the Product in an arm\u2019s length transaction.", "snippet_links": [{"key": "bona-fide", "type": "definition", "offset": [16, 25]}, {"key": "sale-of-the-product", "type": "clause", "offset": [37, 56]}], "size": 5, "hash": "c357b8e22e7f435a4905d15aed1d8b37", "id": 10}], "next_curs": "Cl4SWGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjoLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIaY29tbWVyY2lhbC1sYXVuY2gjMDAwMDAwMGEMogECZW4YACAA", "definition": {"title": "Commercial Launch", "snippet": "means, with respect to a Product, the first commercial sale of such Product to a Third Party occurring after Regulatory Approval for such Product.", "size": 307, "id": "commercial-launch", "examples": ["Savient wishes BTG, and BTG is willing, to supply Bulk Product for <strong>Commercial Launch</strong> and further commercial sales.", "Both Parties agree that the implementation of the NRTRDE procedure will begin on a date mutually agreed by the Parties in writing, through a <strong>Commercial Launch</strong> Letter, signed by both parties (such date being the \u201cNRTRDE Date\u201d).", "Prior to the occurrence of the U.S. <strong>Commercial Launch</strong>, within thirty (30) days after each of June 30 and December 31 in each calendar year, Parent shall provide the Rights Agent with a written report describing in reasonable detail the activities Parent and its Affiliates have undertaken in the preceding 6-month period to develop, achieve U.S. <strong>Commercial Launch</strong> of and seek FDA Approval for the Product (each, a \u201cStatus Report\u201d).", "Dependent upon Company\u2019s receipt of required information being received in a timely fashion, Company will, within ten (10) days of the <strong>Commercial Launch</strong> Date, feature Sprint on Company\u2019s web site.", "Following the First <strong>Commercial Launch</strong> of Licensed Product, NEWLINK shall pay to CIHS a minimum annual royalty as follows: Prior to December 31 of the calendar year in which the first Licensed Product is Commercially Launched, NEWLINK shall pay to CIHS [*] (\u201cInitial Payment\u201d).", "Within 90 days after the end of each calendar quarter following the <strong>Commercial Launch</strong> of the Product by Coronado for which Revogenex is entitled to Royalty payments pursuant to Section 12.1, Coronado shall pay the amount owed on Net Sales generated during such calendar quarter.", "Prior to and continuously after the <strong>Commercial Launch</strong> Date, Company will create marketing and promotional materials concerning the Application(s) and its availability over the Systems in accordance with the terms of this Agreement, including but not limited to the Trademark requirements set forth in Section 21 of the Agreement.", "Both parties acknowledge that a <strong>Commercial Launch</strong> shall not mean any ATG trial conducted by AirCell using twenty (20) airplanes of any individual airline for up to a maximum one hundred twenty (120) calendar days (each a \u201cTrial\u201d), and that AirCell shall be permitted to conduct Trials with an unlimited number of airlines.", "The JSC will meet at such frequency as will be established by the Parties (but not less frequently than four times per year prior to <strong>Commercial Launch</strong> and during the first five years of Commercialization, if so requested by a Party).", "If LICENSOR desires to make a material modification to the Information Service, it may do so upon written notice to AT&amp;T, with AT&amp;T\u2019s reasonable written approval and AT&amp;T Acceptance Testing and re-certification of the Information Service prior to initiating the <strong>Commercial Launch</strong> of the modified Information Service."], "related": [["commercial-sale", "Commercial Sale", "Commercial Sale"], ["launch", "Launch", "Launch"], ["commercial-product", "Commercial Product", "Commercial Product"], ["first-commercial-sale", "First Commercial Sale", "First Commercial Sale"], ["commercial-production", "Commercial Production", "Commercial Production"]], "related_snippets": [], "updated": "2025-12-23T05:49:05+00:00"}, "json": true, "cursor": ""}}